The Role of Screening in Early Diagnosis of Breast Cancer
Keywords:
breast cancer, screening, tumor markers, risk factors, mortality reduction, survival, mammographyAbstract
The article presents data on early diagnosis of breast cancer. A comprehensive analysis of statistical data and risk factors for breast cancer, the use of self-examination, mammographic screening and the determination of tumor markers is carried out. Early detection of breast cancer reaches 80% with mammographic screening and, accordingly, the mortality rate is reduced by 20-30%.
References
Высоцкая И. В. Скрининг рака молочной железы: ситуация в России // Онкология сегодня № 4–2013/№ 1–2014. С. 10.
Давыдов М. И., Ганцев Ш. Х. Онкология 2010, С. 42, С. 377
Давыдов М. И., Ганцев Ш. Х. Онкология 2010, С. 42, С. 377.
Доброкачественная дисплазия молочной железы. Клинические рекомендации. Министерство здравоохранения Российской Федерации, 2020.
Довгалюк А.З. рак молочной железы. С.-Пб., НТФФ “Полисан”;2001.с. 47-8
Любченко Л.Н. Наследственный рак молочной железы и/или яичников: ДНК-диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дис. … д-ра мед. наук, 2009. 281 с. Lyubchenko L.N. Hereditary breast and/or ovarian cancer: DNA diagnostics, individual prognosis, treatment, and prevention. Summary of thesis … of doctor of medical sciences, 2009. 281 p. (In Russ.)
Роль и место скрининговой маммографии в диагностике рака IN SITU. Л.Е. Комарова. ГУ РОНЦ им Н.Н. Блохина РАМН, Москва // Опухоли женской репродуктивной системы. – 2008. – № 3. – С. 20-23.
Семиглазов В. Ф. Что лучше: маммографический скрининг или системное лечение? // Злокачественные опухоли. – 2014. –№ 4. – С. 3 – 9.
Семиглазов В. Ф., Моисеенко В. М. Программа «Россия» (СанктПетербург) ВОЗ по оценке эффективности самообследования молочной железы // Матер. I съезда онкологов СНГ, г. Москва, 1996. – Ч. 2. – С. 41
Семиглазов В.Ф., Манихас А.Г., Моисеенко В.М. и др. Результаты проспективного рандомизированного исследования значения самообследования в раннем выявлении рака молочной железы. Вопросы онкологии 2003;(4):434–41.
Хайленко В.А. Ранняя диагностика рака молочной железы info@oncology.ru
Чёрная а.В., Канаев C.В., новиков С.н. и др. диагностическая значимость маммографии и маммосцинтиграфии с 99м Тс-MIBI при выявлении минимального рака молочной железы // Вопросы онкологии. — 2017. — Т. 63. — № 2. — C. 274-280.
Ebeling F., Stieber P., Untch M. et al. Serum CEA and CA 15–3 as prognostic factors in primary breast cancer // Br. J. Cancer. – 2002; 86:1217–1222.
Gotzsche P., Jorgensen K. Screening for breast cancer with mammography (review). The Cochrane collaboration. The Cochrane library 2013, issne G., pp. 1–17.
Kuhl C., Weigel S., Schrading S. et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010; 28(9):1450–7. DOI: 10.1200/JCO.2009.23.0839
Boyd NF, Huszti E, Melnichouk O et al. Mammographic features associated with interval breast cancers in screening programs. Breast Cancer Res 2014; 16 (4): 417.
Boyd NF. Mammographic density and risk of breast cancer. Am Soc Clin Oncol Educ Book 2013.
Brandt A., Lorenzo Bermejo J., Sundquist J. et al. Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start? Breast Cancer Res Treat 2010; 121(1):133–41.
Claus EB, Risch N., Thompson WD Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73(3):643–51.
D'Alessandro R., Roselli M., Ferroni P. et al. Serum tissue polypeptide specific antigen (TPS): A complementary tumor marker to CA 15–3 in the management of breast cancer // Breast. Cancer. Res. Treat. – 2001; 68:
De La Lande B., Hacene K., Floiras J. et al. Prognostic value of CA 15.3 kinetics for metastatic breast cancer // Int. J Biol. Markers. – 2002; 17: 231–238.
Elmore JG, Barton MB, Moceri VM et al. Ten-year risk of false positive screening mammograms and clinical breast examinations // N. Engl. J. Med. – 1998. – Vol. 338, N 16. – P. 1089–1096. Tabar L., Chen HH, Fagerberg G. et al. Recent results from the
Elmore JG, Barton MB, Moceri VM et al. Ten-year risk of false positive screening mammograms and clinical breast examinations // N. Engl. J. Med. – 1998. – Vol. 338, N 16. – P. 1089–1096.
Forskningsrad N. Research-based evaluation of the Norwegian Breast Cancer Screening Program Final Report // Oslo: Norges forskningsrd , 2015.
Gion M, Boracchi P, Dittadi R, et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers: An old player for a new game // Eur. J. Cancer. – 2002; 38:1181–1188.
Hettipathirana T., Macdonald C., Xie J. et al. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations. Med J Aust 2021; 215(10):460–4. DOI: 10.5694 / mja 2.51226
Humphrey LJ, Helfand M, Chan BK et al. Breast cancer screening: a summary of the evidence for the US preventive Services Task Force. Ann Intern Med. 2012 – Vol. 137(5). – pp. 347–360.
Humphrey L., Chan BKS, Detlefsen S., Helfand M. Screening for breast cancer: systematic evidence review. Ann Int Med 2002. DOI: 10.1059/0003-4819-151-10-200911170-00009
Khatcheressian JL, Wolff A, Smith T et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting // J. Clin . Oncol . – 2006; 24:5091–5097.
Marmot MG. Altman DG. Cameron DA. et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer , 2013-vol. 108(11). – pp.2205–2240.
Profilaktyka raka szyjki macicy - NFZ [Internet]. [Cited 2021.
Sessa C., Balmaña J., Bober SL et al. ESMO Guidelines Committee. Risk Reduction and Screening of Cancer in Hereditary BreastOvarian
Sickles EA. Mammographic features of "early" breast cancer. Am J Roentgenol 1984; 143 (3): 461–4. 57. Kolyadina IV. Heterogeneity of early breast cancer: biological, population, and prognostic significance. Diss . … Dr. of Medicine. Moscow, 2015. [ Kolyadina IV Geterogennost ' rannego raka dairy glands : biological , popular and prognostic znachenie . Dis. ... d- ra med. nauk . Moscow, 2015 (in Russian)..
Sidoni A., Cavaliere A., Bellezza G. et al. Breast cancer in young women: clinicopathological features and biological specificity. Breast 2003; 12(4):247–50. DOI: 10.1016/S0960-9776(03)00095-X
Silva O.E., Zurridia S. Breast cancer. A Practical Guide. Toronto; Novartis Oncology, 2005. p. 41-3.
Chessa F. et al. scintimammography with high resolution dedicated breast camera and mammography in multifocal, multicentric and bilateral breast cancer detection // QJ nucl . Med. Mol. Imaging. - 2009. - Vol. 53. - P. 133-143.
Thomas D., Gao D. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002; 94(19):1445–57. DOI: 10.1093 /JNCI/ 94.19.1445
Tondini C., Hayes D., Gelman R. et al. Comparison of CA15–3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer // Cancer. Res . – 1988; 48:4107–4112.
Tornberg SA. Screening for early detection of cancer – ethical aspects // Acta Oncol . – 1999. – Vol.38. – pp. 77–81.
Villeirs G, Mortier M, De Potter C et al. Breast calcifications. J Belge Radiol 1995; 78 (1): 11–7.
Gofur-Okhunov , M. A., Yigitaliyev , A. B., & Karimov , O. M. (2024). Morphological Features and Methods of Treatment of the Diffuse Form of Breast Cancer. International Journal of Alternative and Contemporary Therapy , 2 (6), 20-29.
